182
Participants
Start Date
June 2, 2016
Primary Completion Date
May 31, 2018
Study Completion Date
November 19, 2018
Placebo
Solution for infusion, 0,9% saline
Dapirolizumab pegol (DZP)
Solution for infusion
Sl0023 313, Lake Success
Sl0023 327, Stockbridge
Sl0023 324, Atlanta
Sl0023 322, DeBary
Sl0023 301, Miami Lakes
Sl0023 321, Miami
Sl0023 310, Tampa
Sl0023 304, Clearwater
Sl0023 319, Palm Harbor
Sl0023 312, Birmingham
Sl0023 308, Memphis
Sl0023 315, Jackson
Sl0023 305, Oklahoma City
Sl0023 303, Houston
Sl0023 317, Amarillo
Sl0023 320, Idaho Falls
Sl0023 306, Albuquerque
Sl0023 311, Los Angeles
Sl0023 314, Thousand Oaks
Sl0023 302, Upland
Sl0023 307, El Cajon
Sl0023 309, El Cajon
Sl0023 323, Huntington Beach
Sl0023 328, Spokane
Sl0023 326, New Haven
Sl0023 101, Plovdiv
Sl0023 102, Plovdiv
Sl0023 202, Providencia
Sl0023 203, Providencia
Sl0023 201, Puerto Varas
Sl0023 204, Viña del Mar
Sl0023 213, Barranquilla
Sl0023 212, Bogotá
Sl0023 214, Bogotá
Sl0023 216, Bucaramanga
Sl0023 211, Chía
Sl0023 215, Medellín
Sl0023 341, Hanover
Sl0023 113, Leipzig
Sl0023 124, Debrecen
Sl0023 225, Guadalajara
Sl0023 224, León
Sl0023 221, México
Sl0023 222, San Luis Potosí City
Sl0023 232, Arequipa
Sl0023 231, Lima
Sl0023 234, Lima
Sl0023 235, Lima
Sl0023 133, Bytom
Sl0023 138, Lodz
Sl0023 136, Lublin
Sl0023 131, Poznan
Sl0023 134, Sosnowiec
Sl0023 135, Warsaw
Sl0023 146, Brasov
Sl0023 142, Bucharest
Sl0023 144, Cluj-Napoca
Sl0023 141, Galati
Sl0023 157, Kazan'
Sl0023 156, Kemerovo
Sl0023 152, Saint Petersburg
Sl0023 155, Voronezh
Sl0023 151, Yaroslavl
Sl0023 153, Yekaterinburg
Sl0023 161, Barcelona
Sl0023 162, Madrid
Sl0023 166, Santa Cruz de Tenerife
Sl0023 172, Kyiv
Sl0023 175, Kyiv
Sl0023 171, Odesa
Sl0023 173, Vinnytsia
UCB Biopharma S.P.R.L.
INDUSTRY